These NOD.HLA-A2/Kb mice express a transgene containing a human-mouse chimeric major histocompatibility class I protein composed of the human HLA-A2.1 joined to the mouse H2-Kb and exhibit HLA-A2.1-restricted CD8 T-cell responses to appropriate antigens.
Linda Sherman, The Scripps Research Institute
Genetic Background | Generation |
---|---|
|
Allele Type |
---|
Transgenic (Inserted expressed sequence, Humanized sequence) |
Transgenic mice are viable, fertile, normal in size and do not display any behavioral abnormalities. FACs analysis indicates expression of HLA-A201 on peripheral blood lymphocytes. The level of expression of this chimeric MHC I molecule in transgenic mice is similar to the observed expression in human PBL's. Diabetes incidence of mice carrying this transgene (88%) is similar to NOD (79%) at 25 weeks of age. Splenocytes from transgenic mice immunized with GAD65 peptides together with MHC class II helper peptide were re-stimulated with peptide pulsed irradiated syngeneic APC?s in-vitro 10 days post immunization Transgenic mice immunized with three different GAD65 peptides (position: 144-149, sequence: LLQEYNWEL; position: 114-122, sequence: VMNILLQYV; and position 573-581, sequence: FLIEEIERL) gave vigorous CTL responses when tested by standard chromium release assays. FACs analysis indicates presence of CFSE expression on CD8+ T-cells in transgenic mice given CFSE-labeled CD8+ T cells in the pancrease, but not in the peripheral or pancreatic lymph nodes 4 days post injection. CFSE-positive CD8+ T-cells were absent in the pancreas, peripheral and pancreatic lymph nodes of wildtype mice. This model provides a tool to identify MHC class I epitopes recognized by CD8+ T cells in type 1 diabetes patients, in addition to testing new therapies focusing on restoring immune tolerance.
NOD mice carrying a CD8+ T-cell transgene (HLA-A2/H2-K)1Scr express the alpha 1 and alpha2 domain of the human class 1 molecule, HLA-A201, fused to the alpha 3, transmembrane and cytoplasmic domains of the mouse H-2kb molecule. This transgene was injected into C57BL/6J oocytes. Resulting progeny were backcrossed to NOD for 14 generations. In 2006, The Jackson Laboratory received NOD.Cg-Tg(HLA-A2/H2-K)1Scr/ShrmJ at generation N14.
Expressed Gene | HLA-A2.1, major histocompatibility complex, class I, subtype A2.1, human |
---|---|
Expressed Gene | H2-K, histocompatibility 2, K region, mouse, laboratory |
Site of Expression |
Allele Name | transgene insertion 1, The Scripps Research Institute |
---|---|
Allele Type | Transgenic (Inserted expressed sequence, Humanized sequence) |
Allele Synonym(s) | CyHLA A2.1/Kb |
Gene Symbol and Name | Tg(HLA-A2/H2-K)1Scr, transgene insertion 1, The Scripps Research Institute |
Gene Synonym(s) | |
Promoter | HLA-A, major histocompatibility complex, class I, A, human |
Expressed Gene | HLA-A2.1, major histocompatibility complex, class I, subtype A2.1, human |
Expressed Gene | H2-K, histocompatibility 2, K region, mouse, laboratory |
Strain of Origin | C57BL/6J |
Chromosome | UN |
Molecular Note | The transgene expresses a human-mouse chimeric major histocompatibility class I protein composed of the leader sequence and the alpha1 and alpha2 domains of HLA-A2.1 joined to the alpha3, cytoplasmic and transmembrane domains of H2-Kb. Mice expressing this transgene exhibit HLA-A2.1-restricted CD8 T-cell responses to appropriate antigens. |
Mutations Made By | Linda Sherman, The Scripps Research Institute |
When using the NOD.HLA-A2/Kb mouse strain in a publication, please cite the originating article(s) and include JAX stock #005853 in your Materials and Methods section.
Facility Barrier Level Descriptions
Service/Product | Description | Price |
---|---|---|
Hemizygous or Non carrier for Tg(HLA-A2/H2-K)1Scr |
Terms are granted by individual review and stated on the customer invoice(s) and account statement. These transactions are payable in U.S. currency within the granted terms. Payment for services, products, shipping containers, and shipping costs that are rendered are expected within the payment terms indicated on the invoice or stated by contract. Invoices and account balances in arrears of stated terms may result in The Jackson Laboratory pursuing collection activities including but not limited to outside agencies and court filings.
The Jackson Laboratory has rigorous genetic quality control and mutant gene genotyping programs to ensure the genetic background of JAX® Mice strains as well as the genotypes of strains with identified molecular mutations. JAX® Mice strains are only made available to researchers after meeting our standards. However, the phenotype of each strain may not be fully characterized and/or captured in the strain data sheets. Therefore, we cannot guarantee a strain's phenotype will meet all expectations. To ensure that JAX® Mice will meet the needs of individual research projects or when requesting a strain that is new to your research, we suggest ordering and performing tests on a small number of mice to determine suitability for your particular project. We do not guarantee breeding performance and therefore suggest that investigators order more than one breeding pair to avoid delays in their research.
What information were you hoping to find through your search?
How easy was it to find what you were looking for?
We may wish to follow up with you. Enter your email if you are happy for us to connect and reachout to you with more questions.
Please Enter a Valid Email Address
Thank you for sharing your feedback! We are working on improving the JAX Mice search. Come back soon for exciting changes.